Person:
ARTAN, AYŞE SERRA

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
AYŞE SERRA
Last Name
ARTAN
Name
Email Address
Birth Date

Filters

2019 - 201932020 - 20222
Reset filters

Settings

Author: KAZANCIOĞLU, RÜMEYZA ×

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of kidney functions in patients on chemotherapy
    (2019-07-23) Kazancıoğlu, Rümeyza; Elçioğlu, Ömer Celal; Gürsu, Meltem; Artan, Ayşe Serra; Şeker, Mesut; Türk, Hacı Mehmet; Haziyev, Elgun; KAZANCIOĞLU, RÜMEYZA; ELÇİOĞLU, ÖMER CELAL; GÜRSU, MELTEM; ARTAN, AYŞE SERRA; ŞEKER, MESUT; TÜRK, HACI MEHMET
  • Thumbnail Image
    PublicationOpen Access
    Correlation of Body Composition Analysis with Anthropometric Measurements in Peritoneal Dialysis Patients
    (2022-01-01T00:00:00Z) ARTAN, AYŞE SERRA; GÜRSU, Meltem; ELÇİOĞLU, Ömer Celal; YABACI TAK, AYŞEGÜL; KAZANCIOĞLU, Rümeyza; ARTAN, AYŞE SERRA; GÜRSU, MELTEM; ELÇİOĞLU, ÖMER CELAL; YABACI TAK, AYŞEGÜL; KAZANCIOĞLU, RÜMEYZA
    Objective: This study investigates correlations between different methods for diagnosis of protein energy malnutrition (PEM) in peritoneal dialysis patients. Methods: Twenty four patients were included. Patients with amputations, infections, peritonitis, malignancies and PD duration less than three months were excluded. Physical examination findings, laboratory results and anthropometric measurements were recorded. Body composition analysis was performed with multi-frequency bioimpedance analyzer. Dialysis malnutrition score (DMS) was calculated. The correlations of different parameters were searched. Results: Eleven patients were female and 13 patients were male. Mean age was 58.9±12.6 years. Median dialysis duration was 25 (interquartile range: 14) months. Protein percentage was negatively correlated with fat percentage (r=-0.785; p<0.001), triceps skinfold thickness (SFT) (r=-0.641; p<0.001), biceps SFT (r=-0.685; p<0.001), body mass index (BMI) (r=-0.867; p<0.001), mid-arm circumference (r=-0.680; p=0.001). Fat percentage was positively correlated with BMI (r=0.780; p<0.001), biceps SFT (r=0.817; p<0.001), triceps SFT (r=0.901; p<0.001) and mid-arm circumference (r=0.558; p=0.005) Albumin was negatively correlated with DMS (r= -0.439; p=0.032). DMS and albumin were not correlated with bioimpedance and anthropometry Conclusion: Albumin is a marker of PEM in PD patients. Malnutrition scores may be used as adjunct methods. Increase in fat mass and percentage may influence the interpretation of anthropometric measurements.
  • Thumbnail Image
    PublicationOpen Access
    Evaluation of Kidney Function in Patients on Chemotherapy
    (2021-04-01T00:00:00Z) Haziyev, Elgun; GÜRSU, Meltem; ŞEKER, Mesut; ELÇİOĞLU, Ömer Celal; ARTAN, AYŞE SERRA; ALİYEV, Altay; TÜRK, HACI MEHMET; DEMİR, Tarık; TOPRAK, ALİ; KAZANCIOĞLU, Rümeyza; GÜRSU, MELTEM; ŞEKER, MESUT; ELÇİOĞLU, ÖMER CELAL; ARTAN, AYŞE SERRA; ALİYEV, ALTAY; TÜRK, HACI MEHMET; DEMİR, TARıK; TOPRAK, ALİ; KAZANCIOĞLU, RÜMEYZA
    Objective: We aimed to study whether long-term kidney function would be affected by different chemotherapy regimens in patients with malignancy.
  • No Thumbnail Available
    PublicationMetadata only
    Oral Anticoagulant Treatment of Atrial Fibrillation in Chronic Kidney Disease Patients
    (2019-07-01) ARTAN, AYŞE SERRA; GÜRSU, MELTEM; ELÇİOĞLU, ÖMER CELAL; KAZANCIOĞLU, RÜMEYZA; ARTAN, AYŞE SERRA; GÜRSU, MELTEM; ELÇİOĞLU, ÖMER CELAL; KAZANCIOĞLU, RÜMEYZA
    Nonvalvular atrial fibrillation is the most prevalent sustained arrhythmia in chronic kidney disease patients. When compared to warfarin, new oral anticoagulants are found to be non-inferior or superior in safety and efficacy outcomes in the general population. The efficacy and safety of anticoagulation in mild chronic kidney disease is similar to the general population. Studies are yielding conflicting results in moderate to advanced chronic kidney disease and end stage renal disease. Due to hemostasis dysfunction in chronic kidney disease, both bleeding and thromboembolism risk increase. Advanced chronic kidney disease and end stage renal disease patients are excluded from randomized controlled trials. Our knowledge about the efficacy, safety and dose adjustments of warfarin and new oral anticoagulants are based on observational data. According to the recent studies, apixaban and edoxaban use in moderate chronic kidney disease with a glomerular filtration rate between 30-50 mL/min may be safer than warfarin. There are no high quality evidence to recommend the use of warfarin in advanced and end stage chronic kidney disease patients. The Food and Drug Administration approved the use of apixaban in end stage renal disease. Randomized controlled trials are needed to evaluate the use of oral anticoagulants in advanced chronic kidney disease.
  • Thumbnail Image
    PublicationOpen Access
    Extreme Hyperkalemia in a Hemodialysis Patient Presenting with Cardiac Arrhythmia
    (2019-10-01) ARTAN, AYŞE SERRA; GÜRSU, Meltem; ELÇİOĞLU, Ömer Celal; Deligoz Bildaci, Yelda; KAZANCIOĞLU, RÜMEYZA; ARTAN, AYŞE SERRA; GÜRSU, MELTEM; ELÇİOĞLU, ÖMER CELAL; DELİGÖZ BİLDACI, YELDA; KAZANCIOĞLU, RÜMEYZA
    Hyperkalemia is commonly seen in hemodialysis patients and is a potentially life-threatening condition. Serum potassium concentration greater than 10 mEq/L is defined as extreme hyperkalemia. Emergent treatment of hyperkalemia is made with intravenous calcium, insulin-dextrose solutions, diuretics, gastrointestinal cation-exchange resin and dialysis. We present here a 52-year-old chronic hemodialysis patient with extreme hyperkalemia and cardiac arrhythmia. She was treated with emergent hemodialysis. Her abnormal laboratory findings and electrocardiography recovered. Further examinations suggested insufficient hemodialysis treatment as the possible cause of hyperkalemia.